易方达、中欧、建信等旗下第二批浮动费率基金，开卖！

Core Viewpoint - The second batch of floating rate funds is set to launch on August 4, with 12 new funds approved, expanding the market for this fund type [1][3]. Group 1: Fund Launch Details - The first batch of 26 floating rate funds raised nearly 26 billion yuan by the end of May [2]. - The second batch includes three funds: E Fund Value Return, China Universal Core Selection, and CCB Medical Innovation, with specific fundraising deadlines [3]. - CCB Medical Innovation has a fundraising cap of 3 billion yuan, while the other two funds do not have a cap [4]. Group 2: Fund Management and Fee Structure - The three funds are managed by experienced professionals, with E Fund's manager holding a master's degree in financial mathematics and CCB's manager being a graduate of Peking University [4]. - The fee structure for the funds includes three tiers: 1.2% (base), 1.5% (up), and 0.6% (down), depending on performance relative to benchmarks [4]. Group 3: Performance Benchmarks - E Fund Value Return's benchmark is a combination of various indices, including the CSI 800 Index and the China Bond Total Index [5]. - China Universal Core Selection's benchmark is primarily based on the CSI 800 Index and other indices [5]. - CCB Medical Innovation's benchmark includes the CSI Pharmaceutical Health Index and the Hang Seng Healthcare Index [5]. Group 4: Industry Trends and Future Outlook - The launch of floating rate funds aligns with the regulatory push for high-quality development in the public fund industry, emphasizing performance-linked fee structures [6]. - The second batch of funds includes industry or thematic products, indicating a shift from broad market selection to more specialized strategies [6]. - Fund companies are expected to continue launching floating rate products, with a target of at least 60% of their active management equity fund issuance [7].